Sequana Medical NV has announced the US FDA approval of its Alfapump system for treating recurrent or refractory ascites due to liver cirrhosis. This approval marks Alfapump as the first active ...
The current standard treatment involves therapeutic ... The US market of recurrent and refractory ascites due to liver cirrhosis is forecast to grow by an average of 9% per year, from approximately 70 ...
In a matter of a few months, he went from a NASH diagnosis ... including the treatment of conditions like MASLD. Given the clear connection between obesity and liver disease, it’s critical ...
This study highlights that metabolic disorders resulting from bacterial imbalance in the liver are significant contributors to the pathogenesis of NAFLD, and investigating the relationship between ...
A Closer Look At These Complex Diseases Johnson & Johnson is the only pharmaceutical company investigating a treatment for three segments of debilitating auto- and alloantibody diseases ...